Gene Activity List

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Gene Compound Experiment Study Pathway Assay Report Bug Request Feature
Gene Activity List
You are on Page 79 of 1714:
69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89
Gene Compound Assay Inh Ic50 Ki View
calcium channel, voltage-dependent, N type, alpha 1B subunit GUANETHIDINE Calcium Channel Type L, Benzothiazepine 54% NoneNone NoneNone View
calcium channel, voltage-dependent, alpha2/delta subunit 1 GUANETHIDINE Calcium Channel Type L, Benzothiazepine 54% NoneNone NoneNone View
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 PERGOLIDE Serotonin Transporter 54% NoneNone NoneNone View
Cytochrom P450-2C19 monooxygenase FLUCONAZOLE CYP450-2C19 Inhibition 54% NoneNone NoneNone View
adenosine A2a receptor GW-1929 Adenosine A2A 54% 37.254uM 20.915uM View
Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) KETOCONAZOLE CYP450-2C9 Inhibition 54% NoneNone NoneNone View
cytochrome P450, family 2, subfamily C, polypeptide 9 KETOCONAZOLE CYP450-2C9 Inhibition 54% NoneNone NoneNone View
mitogen activated protein kinase 1 TYRPHOSTIN A23 Protein Serine/Threonine Kinase, ERK2 54% NoneNone NoneNone View
mitogen-activated protein kinase 1 TYRPHOSTIN A23 Protein Serine/Threonine Kinase, ERK2 54% NoneNone NoneNone View
mitogen activated protein kinase 3 AURANOFIN Protein Serine/Threonine Kinase, ERK1 54% NoneNone NoneNone View
mitogen-activated protein kinase 3 AURANOFIN Protein Serine/Threonine Kinase, ERK1 54% NoneNone NoneNone View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 4 LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
gamma-aminobutyric acid A receptor, gamma 1 LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
gamma-aminobutyric acid A receptor, pi LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
AT hook, DNA binding motif, containing 1 (DBSS) LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
gamma-aminobutyric acid A receptor, theta LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
gamma-aminobutyric acid A receptor, gamma 2 LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
sodium channel associated protein 1 CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel associated protein 2 CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type III, beta CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type I, alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type IX, alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type VII, alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
amiloride-sensitive cation channel 5, intestinal CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type III, beta CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type VIII, alpha polypeptide CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type XI, alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type I, beta CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type 10, alpha polypeptide CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, alpha polypeptide CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type V, alpha polypeptide CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type II, beta CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 gamma CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 beta CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type XI, alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1, gamma CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1, delta CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type X, alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type IX, alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage gated, type VIII, alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type VII, alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, beta CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type III, alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type II, beta CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type II, alpha 2 CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type I, beta CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
sodium channel, voltage-gated, type I, alpha CLOZAPINE Sodium Channel, Site 2 53% NoneNone NoneNone View
mitogen activated protein kinase 3 THIOGUANINE Protein Serine/Threonine Kinase, ERK1 53% 5.516uM NoneNone View
mitogen-activated protein kinase 3 THIOGUANINE Protein Serine/Threonine Kinase, ERK1 53% 5.516uM NoneNone View
solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 DEXTROMETHORPHAN Adrenergic, Norepinephrine Transporter 53% NoneNone NoneNone View
adrenergic receptor, alpha 1a DEXTROMETHORPHAN Adrenergic alpha1A 53% NoneNone NoneNone View
sodium channel, voltage-gated, type II, beta DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, nonvoltage-gated 1 alpha DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, nonvoltage-gated 1 gamma DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, nonvoltage-gated 1 beta DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, voltage-gated, type XI, alpha DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, nonvoltage-gated 1, gamma DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, nonvoltage-gated 1, delta DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, nonvoltage-gated 1 alpha DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, voltage-gated, type X, alpha DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, voltage-gated, type IX, alpha DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, voltage gated, type VIII, alpha DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, voltage-gated, type VII, alpha DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) DICLOFENAC Sodium Channel, Site 2 53% 53.142uM 47.644uM View
phosphodiesterase 3B MICONAZOLE Phosphodiesterase PDE3 53% 73.911uM NoneNone View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage-gated, type XI, alpha S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1, gamma S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1, delta S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 alpha S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage-gated, type X, alpha S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage-gated, type IX, alpha S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage gated, type VIII, alpha S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage-gated, type VII, alpha S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, beta S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, alpha S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage-gated, type III, alpha S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage-gated, type II, beta S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage-gated, type II, alpha 2 S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage-gated, type I, beta S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
sodium channel, voltage-gated, type I, alpha S-(-)-PROPRANOLOL Sodium Channel, Site 2 52% NoneNone NoneNone View
5-hydroxytryptamine (serotonin) receptor 2B DISULFIRAM Serotonin 5-HT2B 52% 34.547uM 21.984uM View
adrenergic receptor, alpha 1a KETOCONAZOLE Adrenergic alpha1A 52% 35.729uM 14.462uM View
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 SIMVASTATIN Dopamine Transporter 52% NoneNone NoneNone View
Cytochrom P450-1A2 monooxygenase AURANOFIN CYP450-1A2 Inhibition 52% NoneNone NoneNone View
matrix metallopeptidase 9 CAMPTOTHECIN Protease, Matrix Metalloprotease-9 (MMP-9) 52% NoneNone NoneNone View
matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) CAMPTOTHECIN Protease, Matrix Metalloprotease-9 (MMP-9) 52% NoneNone NoneNone View
mitogen activated protein kinase 14 DIETHYLSTILBESTROL Protein Serine/Threonine Kinase, p38alpha 52% 32.903uM NoneNone View
mitogen-activated protein kinase 14 DIETHYLSTILBESTROL Protein Serine/Threonine Kinase, p38alpha 52% 32.903uM NoneNone View
estrogen receptor 1 4-OCTYLPHENOL Estrogen ERalpha 52% 27.674uM 7.907uM View
estrogen receptor 1 4-OCTYLPHENOL Estrogen ERalpha 52% 27.674uM 7.907uM View
5-hydroxytryptamine (serotonin) receptor 1A BACITRACIN Serotonin 5-HT1A 52% NoneNone NoneNone View
dopamine receptor D4 ALPHA-ERGOCRYPTINE Dopamine D4.2 52% NoneNone NoneNone View
dopamine receptor D3 CLOSANTEL Dopamine D3 52% NoneNone NoneNone View
mitogen activated protein kinase 14 GRAMICIDIN Protein Serine/Threonine Kinase, p38alpha 52% NoneNone NoneNone View
mitogen-activated protein kinase 14 GRAMICIDIN Protein Serine/Threonine Kinase, p38alpha 52% NoneNone NoneNone View
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 MAPROTILINE Serotonin Transporter 52% NoneNone NoneNone View
adrenergic receptor, alpha 1b BUSPIRONE Adrenergic alpha1B 52% NoneNone NoneNone View
adrenergic receptor, alpha 2a BUSPIRONE Adrenergic alpha2A 52% NoneNone NoneNone View
chemokine (C-C motif) receptor 5 OXCARBAZEPINE Chemokine CCR5 52% NoneNone NoneNone View
Cytochrom P450-1A2 monooxygenase ERGOTAMINE CYP450-1A2 Inhibition 52% NoneNone NoneNone View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 4 VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
gamma-aminobutyric acid A receptor, gamma 1 VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
gamma-aminobutyric acid A receptor, pi VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
AT hook, DNA binding motif, containing 1 (DBSS) VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
gamma-aminobutyric acid A receptor, theta VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
gamma-aminobutyric acid A receptor, gamma 2 VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 6 VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 5 VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
gamma-aminobutyric acid A receptor, alpha 2 VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
gamma-aminobutyric acid A receptor, alpha 1 VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 2 VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 1 VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
gamma-aminobutyric acid A receptor, delta VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 3 VX-745 GABAA, Benzodiazepine, Central 52% 11.986uM 9.767uM View
dopamine receptor D1A TERCONAZOLE Dopamine D1 52% 25.48uM 12.74uM View
androgen receptor NELFINAVIR Testosterone 52% 36.389uM 24.259uM View
5-hydroxytryptamine (serotonin) receptor 1B TERCONAZOLE Serotonin 5-HT1B 52% 89.897uM 40.862uM View
sodium channel, voltage-gated, type II, alpha 2 ERGOTAMINE Sodium Channel, Site 2 51% NoneNone NoneNone View
sodium channel, voltage-gated, type I, beta ERGOTAMINE Sodium Channel, Site 2 51% NoneNone NoneNone View
sodium channel, voltage-gated, type I, alpha ERGOTAMINE Sodium Channel, Site 2 51% NoneNone NoneNone View
sodium channel, voltage-gated, type V, alpha polypeptide VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type II, beta VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, nonvoltage-gated 1 alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, nonvoltage-gated 1 gamma VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, nonvoltage-gated 1 beta VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type XI, alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, nonvoltage-gated 1, gamma VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, nonvoltage-gated 1, delta VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, nonvoltage-gated 1 alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type X, alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type IX, alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage gated, type VIII, alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type VII, alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type IV, beta VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type IV, alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type III, alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type II, beta VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type II, alpha 2 VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type I, beta VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type I, alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type IV, beta VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel associated protein 1 VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel associated protein 2 VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type III, beta VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type I, alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type IX, alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type VII, alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
amiloride-sensitive cation channel 5, intestinal VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type III, beta VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type XI, alpha VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type I, beta VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type 10, alpha polypeptide VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
sodium channel, voltage-gated, type IV, alpha polypeptide VX-745 Sodium Channel, Site 2 51% 26.533uM 23.788uM View
adrenergic receptor, alpha 2a HYDROXYPROGESTERONE Adrenergic alpha2A 51% NoneNone NoneNone View
melanocortin 5 receptor PIPAMAZINE Melanocortin MC5 51% NoneNone NoneNone View
dopamine receptor D3 FENOFIBRATE Dopamine D3 51% 137.533uM 46.709uM View
Cytochrom P450-2C19 monooxygenase DANAZOL CYP450-2C19 Inhibition 51% NoneNone NoneNone View
matrix metalloproteinase 1 (interstitial collagenase) CAMPTOTHECIN Protease, Matrix Metalloprotease-1 (MMP-1) 51% NoneNone NoneNone View
progesterone receptor BETA-ESTRADIOL Progesterone 51% 32.559uM 4.247uM View
progesterone receptor BETA-ESTRADIOL Progesterone 51% 32.559uM 4.247uM View
adenosine A1 receptor NOCODAZOLE Adenosine A1 51% 50.33uM 29.433uM View
thromboxane A synthase 1 LIPOPOLYSACCHARIDE E. COLI O55:B5 Thromboxane Synthetase 51% NoneNone NoneNone View
thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) LIPOPOLYSACCHARIDE E. COLI O55:B5 Thromboxane Synthetase 51% NoneNone NoneNone View
glutamate receptor, ionotropic, N-methyl D-aspartate 2D AMANTADINE Glutamate, NMDA, Phencyclidine 51% 31.983uM 21.666uM View
glutamate receptor, ionotropic, NMDA2C AMANTADINE Glutamate, NMDA, Phencyclidine 51% 31.983uM 21.666uM View
glutamate receptor, ionotropic, N-methyl D-aspartate 2B AMANTADINE Glutamate, NMDA, Phencyclidine 51% 31.983uM 21.666uM View
glutamate receptor, ionotropic, N-methyl D-aspartate 2A AMANTADINE Glutamate, NMDA, Phencyclidine 51% 31.983uM 21.666uM View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 6 LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 5 LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
gamma-aminobutyric acid A receptor, alpha 2 LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
gamma-aminobutyric acid A receptor, alpha 1 LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 2 LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 1 LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
gamma-aminobutyric acid A receptor, delta LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 3 LY-294002 GABAA, Benzodiazepine, Central 54% 21.411uM 17.446uM View
calcium channel, voltage-dependent, gamma subunit 4 MIFEPRISTONE Calcium Channel Type L, Phenylalkylamine 54% 16.01uM 15.559uM View
calcium channel, voltage-dependent, gamma subunit 3 MIFEPRISTONE Calcium Channel Type L, Phenylalkylamine 54% 16.01uM 15.559uM View
calcium channel, voltage-dependent, gamma subunit 2 MIFEPRISTONE Calcium Channel Type L, Phenylalkylamine 54% 16.01uM 15.559uM View
calcium channel, voltage-dependent, gamma subunit 1 MIFEPRISTONE Calcium Channel Type L, Phenylalkylamine 54% 16.01uM 15.559uM View
calcium channel, voltage-dependent, beta 4 subunit MIFEPRISTONE Calcium Channel Type L, Phenylalkylamine 54% 16.01uM 15.559uM View
calcium channel, voltage-dependent, beta 3 subunit MIFEPRISTONE Calcium Channel Type L, Phenylalkylamine 54% 16.01uM 15.559uM View
calcium channel, voltage-dependent, beta 2 subunit MIFEPRISTONE Calcium Channel Type L, Phenylalkylamine 54% 16.01uM 15.559uM View
calcium channel, voltage-dependent, L type, alpha 1S subunit MIFEPRISTONE Calcium Channel Type L, Phenylalkylamine 54% 16.01uM 15.559uM View
calcium channel, voltage-dependent, alpha 1F subunit MIFEPRISTONE Calcium Channel Type L, Phenylalkylamine 54% 16.01uM 15.559uM View
calcium channel, voltage-dependent, L type, alpha 1D subunit MIFEPRISTONE Calcium Channel Type L, Phenylalkylamine 54% 16.01uM 15.559uM View